Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue.


Journal

Archives of pathology & laboratory medicine
ISSN: 1543-2165
Titre abrégé: Arch Pathol Lab Med
Pays: United States
ID NLM: 7607091

Informations de publication

Date de publication:
01 07 2021
Historique:
accepted: 09 03 2021
pubmed: 16 3 2021
medline: 6 7 2021
entrez: 15 3 2021
Statut: ppublish

Résumé

Small case series have evaluated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) detection in formalin-fixed, paraffin-embedded tissue using reverse transcription-polymerase chain reaction, immunohistochemistry (IHC), and/or RNA in situ hybridization (RNAish). To compare droplet digital polymerase chain reaction, IHC, and RNAish to detect SARS-CoV-2 in formalin-fixed, paraffin-embedded tissue in a large series of lung specimens from coronavirus disease 2019 (COVID-19) patients. Droplet digital polymerase chain reaction and RNAish used commercially available probes; IHC used clone 1A9. Twenty-six autopsies of COVID-19 patients with formalin-fixed, paraffin-embedded tissue blocks of 62 lung specimens, 22 heart specimens, 2 brain specimens, and 1 liver, and 1 umbilical cord were included. Control cases included 9 autopsy lungs from patients with other infections/inflammation and virus-infected tissue or cell lines. Droplet digital polymerase chain reaction had the highest sensitivity for SARS-CoV-2 (96%) when compared with IHC (31%) and RNAish (36%). All 3 tests had a specificity of 100%. Agreement between droplet digital polymerase chain reaction and IHC or RNAish was fair (κ = 0.23 and κ = 0.35, respectively). Agreement between IHC and in situ hybridization was substantial (κ = 0.75). Interobserver reliability was almost perfect for IHC (κ = 0.91) and fair to moderate for RNAish (κ = 0.38-0.59). Lung tissues from patients who died earlier after onset of symptoms revealed higher copy numbers by droplet digital polymerase chain reaction (P = .03, Pearson correlation = -0.65) and were more likely to be positive by RNAish (P = .02) than lungs from patients who died later. We identified SARS-CoV-2 in hyaline membranes, in pneumocytes, and rarely in respiratory epithelium. Droplet digital polymerase chain reaction showed low copy numbers in 7 autopsy hearts from ProteoGenex Inc. All other extrapulmonary tissues were negative. Droplet digital polymerase chain reaction was the most sensitive and highly specific test to identify SARS-CoV-2 in lung specimens from COVID-19 patients.

Identifiants

pubmed: 33720333
pii: 462833
doi: 10.5858/arpa.2021-0008-SA
doi:

Substances chimiques

RNA, Viral 0

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

785-796

Auteurs

Anja C Roden (AC)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Julie A Vrana (JA)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Justin W Koepplin (JW)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Angela E Hudson (AE)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Andrew P Norgan (AP)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Garrett Jenkinson (G)

Department of Health Sciences Research (Jenkinson), Mayo Clinic Rochester, Minnesota.

Satoko Yamaoka (S)

Department of Molecular Medicine (Yamaoka, Ebihara), Mayo Clinic Rochester, Minnesota.

Hideki Ebihara (H)

Department of Molecular Medicine (Yamaoka, Ebihara), Mayo Clinic Rochester, Minnesota.

Robert Monroe (R)

Advanced Cell Diagnostics, Newark, California (Monroe).

Matthias J Szabolcs (MJ)

The Department of Pathology and Cell Biology, Columbia University, New York, New York (Szabolcs).

Ramanath Majumdar (R)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Ann M Moyer (AM)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Joaquín J García (JJ)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Benjamin R Kipp (BR)

From the Department of Laboratory Medicine and Pathology (Roden, Vrana, Koepplin, Hudson, Norgan, Majumdar, Moyer, García, Kipp), Mayo Clinic Rochester, Minnesota.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH